The incidence and prevalence of a first-ever spontaneous pneumothorax in patients with chronic obstructive pulmonary disease (COPD) and emphysema are increased significantly in men and in Black patients.
Both stable current smokers and individuals who had quit exhibited significantly less anxiety but more depression.
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
High plasma omega-3 polyunsaturated fatty acid levels have been shown to be associated with a slower progression of percent emphysema.
Patients with asthma-chronic obstructive pulmonary disease overlap may have an increased independent risk for lung cancer that is similar to those with COPD, but higher than smokers with asthma and normal spirometry values.
Cases of e-cigarette or vaping product use–associated lung injury (EVALI) appear to have been overlooked in the past.
Both body mass index and changes in weight have been linked to 1-year mortality risk in patients with fibrotic interstitial lung disease.
In a real-world setting, biologic agents offered diverse clinical benefits in patients with asthma with and without chronic rhinosinusitis.
In patients with chronic rhinosinusitis with nasal polyps, regardless of their asthma status, omalizumab was associated with improvements in nasal polyps score, nasal congestion score, and sinonasal outcome test score.
